# Piramal Pharma (NSE: PPLPHARMA) — share price, financials and shareholding

Source: https://companystockprice.com/stocks/piramal-pharma

## Key facts
- Company: Piramal Pharma Limited
- NSE symbol: PPLPHARMA (BSE code 543635)
- ISIN: INE0DK501011
- Last close: ₹194.89 (-1.56%)

## About
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

## FAQ
**What is the Piramal Pharma company stock price today?**
Piramal Pharma (PPLPHARMA) last traded at ₹194.89 on the NSE, down 1.56% from the previous close.

**What is the market cap of Piramal Pharma?**
Piramal Pharma has a market capitalisation of about ₹25,823 crore.

**What is the 52-week high and low of Piramal Pharma?**
The 52-week high of Piramal Pharma shares is ₹231.93 and the 52-week low is ₹132.30.

**What is the NSE symbol of Piramal Pharma?**
Piramal Pharma trades on the National Stock Exchange of India under the symbol PPLPHARMA, and on the BSE under scrip code 543635. Its ISIN is INE0DK501011.

**When was Piramal Pharma listed on the NSE?**
Piramal Pharma was listed on the NSE on 19 October 2022.

---
Prices may be delayed. Informational only, not investment advice. Methodology: https://companystockprice.com/methodology